CureVac has filed a federal lawsuit accusing Moderna of patent infringement over its mRNA-based COVID-19 vaccine Spikevax. The German biotech claims that Moderna used its proprietary methods for stabilising messenger RNA without authorisation and is seeking monetary damages framed as royalties on Spikevax sales.
ADVERTISEMENT
Tag Archive for: intellectual property
The Unified Patent Court and the unitary patent were established to make patent litigation in Europe easier, faster and more affordable. It has been particularly emphasized that the new system was designed to enable small and medium-sized enterprises to enforce their rights more effectively and rapidly. The reality now suggests differently. Litigation in Europe has become quite fragmented, more complex and more expensive than ever – a nice playground for deep pockets.
Patent disputes are part of everyday life in pharma. What is unusual is the timing. More than three years after the peak of the Covid-19 pandemic, Bayer has launched a broad patent offensive against the makers of mRNA vaccines – just as the market has cooled and the pandemic feels firmly in the rear-view mirror. Understandable from a financial perspective, perhaps, but still raising questions about the timing.


Andrej Lišakov / Unsplash+
Boehmert & Boehmert
Bayer AG